流感新药巴洛沙韦的药理作用及临床评价

doi:10.5246/jcps.2020.10.068

中国药学(英文版) ›› 2020, Vol. 29 ›› Issue (10): 729-733.DOI: 10.5246/jcps.2020.10.068

流感新药巴洛沙韦的药理作用及临床评价

曹晶晶, 孙俊, 赵淑娟, 马培志^*

河南省人民医院药学部; 郑州大学人民医院; 河南大学临床医学院, 河南郑州 450003

收稿日期:2020-07-23 修回日期:2020-09-10 出版日期:2020-10-31 发布日期:2020-09-15
通讯作者: Tel.: +86-371-65581026, E-mail: mpeizhi@163.com

Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil

Jingjing Cao, Jun Sun, Shujuan Zhao, Peizhi Ma^*

Department of Pharmacy, Henan Provincial People’s Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou 450003, China

Received:2020-07-23 Revised:2020-09-10 Online:2020-10-31 Published:2020-09-15
Contact: Tel.: +86-371-65581026, E-mail: mpeizhi@163.com

摘要/Abstract

摘要：

巴洛沙韦是一种聚合酶酸性(PA)内切核酸酶抑制剂, 于2018年10月25日由美国FDA批准上市, 用于治疗12岁及以上无并发症的流感患者。本文对其药效学、药动学、相互作用、临床研究以及不良反应等方面进行了简要综述。

关键词: 巴洛沙韦, 药效学, 药动学, 不良反应

Abstract:

Baloxavir marboxil is a polymerase acidic (PA) endonuclease inhibitor, which is approved by the U.S Food and Drug Administration (FDA) on October 25, 2018, for the treatment of uncomplicated influenza patients aged 12 years and older. In the present work, we reviewed the pharmacodynamics, pharmacokinetics, drug interactions, clinical trials and adverse reactions of baloxavir marboxil.

Key words: Baloxavir marboxil, Pharmacodynamics, Pharmacokinetics, Adverse reactions

中图分类号:

R961

Supporting:

曹晶晶, 孙俊, 赵淑娟, 马培志. 流感新药巴洛沙韦的药理作用及临床评价[J]. 中国药学(英文版), 2020, 29(10): 729-733.

Jingjing Cao, Jun Sun, Shujuan Zhao, Peizhi Ma. Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 729-733.

参考文献

[1] FDA. Highlights of prescribing information. 2018, 10, 24. http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbll.pdf

[2] Takashita, E.; Morita, H.; Ogawa, R.; Nakamura, K.; Fujisaki, S.; Shirakura, M.; Kuwahara, T.; Kishida, N.; Watanabe, S.; Odagiri, T. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front Microbiol. 2018, 9, 3026.

[3] Gonzalez-Motos, V.; Jurgens, C.; Ritter, B.; Kropp, K.A.; Durán,V.; Larsen,O. Varicella zoster virus glycoprotein C increases chemokine-mediated leukocyte migration. PLoS Pathog. 2017, 13, e1006346.

[4] Reich, S.; Guilligay, D.; Pflug, A.; Malet, H.; Berger, I.; Crépin, T.; Hart, D.; Lunardi, T.; Nanao, M.; Ruigrok, R.W.; Cusack, S. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature. 2014, 516, 361–366.

[5] Shi, F.Y.; Xie, Y.C.; Shi, L.F.; Xu, W.F. Viral RNA polymerase: a promising antiviral target for influenza A virus. Curr. Med. Chem. 2013, 20, 3923–3934.

[6] Dias, A.; Bouvier, D.; Crépin, T.; McCarthy, A.A.; Hart, D.J.; Baudin, F.; Cusack, S.; Ruigrok, R.W. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature. 2009, 458, 914–918.

[7] Locke, S.C.; Splawn, L.M.; Cho, J.C. Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza. Drugs Today. 2019, 55, 359–366.

[8] Noshi, T.; Kitano, M.; Taniguchi, K.; Yamamoto, A.; Omoto, S.; Baba, K.; Hashimoto, T.; Ishida, K.; Kushima, Y.; Hattori, K.; Kawai, M.; Yoshida, R.; Kobayashi, M.; Yoshinaga, T.; Sato, A.; Okamatsu, M.; Sakoda, Y.; Kida, H.; Shishido, T.; Naito, A. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018, 160, 109–117.

[9] Heo, Y.A. Baloxavir: first global approval. Drugs. 2018, 78, 693–697.

[10] Watanabe, A.; Ishida, T.; Hirotsu, N.; Kawaguchi, K.; Ishibashi, T.; Shishido, T.; Sato, C.; Portsmouth, S.; Tsuchiya, K.; Uehara, T. Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study. Antiviral Res. 2019, 163, 75–81.

[11] Koshimichi, H.; Ishibashi, T.; Kawaguchi, N.; Sato, C.; Kawasaki, A.; Wajima, T. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin. Drug Investig. 2018, 38, 1189–1196.

[12] Kitano, M.; Matsuzaki, T.; Oka, R.; Baba, K.R.; Noda, T.; Yoshida, Y.; Sato, K.; Yoshida, R.; Sato, A.; Kamimori, H.; Shishido, T.; Naito, A.A. Therapeutic effects of baloxavir marboxil against influenza A virus infection in ferrets. Open Forum Infect. Dis. 2018, 5, S413.

[13] Cole, P. Baloxavir marboxil. Drugs Future. 2018, 43, 379–387.

[14] Hayden, F.G.; Sugaya, N.; Hirotsu, N.; Lee, N.; de Jong, M.D.; Hurt, A.C.; Ishida, T.; Sekino, H.; Yamada, K.; Portsmouth, S.; Kawaguchi, K.; Shishido, T.; Arai, M.; Tsuchiya, K.; Uehara, T.; Watanabe, A.; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 2018, 379, 913–923.

[15] Nair, H.; Brooks, W.A.; Katz, M.; Roca, A.; Berkley, J.A.; Madhi, S.A.; Simmerman, J.M.; Gordon, A.; Sato, M.; Howie, S.; Krishnan, A.; Ope, M.; Lindblade, K.A.; Carosone-Link, P.; Lucero, M.; Ochieng, W.; Kamimoto, L.; Dueger, E.; Bhat, N.; Vong, S.; Theodoratou, E.; Chittaganpitch, M.; Chimah, O.; Balmaseda, A.; Buchy, P.; Harris, E.; Evans, V.; Katayose, M.; Gaur, B.; O’Callaghan-Gordo, C.; Goswami, D.; Arvelo, W.; Venter, M.; Briese, T.; Tokarz, R.; Widdowson, M.A.; Mounts, A.W.; Breiman, R.F.; Feikin, D.R.; Klugman, K.P.; Olsen, S.J.; Gessner, B.D.; Wright, P.F.; Rudan, I.; Broor, S.; Simões, E.A.; Campbell, H. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011, 378, 1917–1930.

[16] Kawaguchi, K.; Portsmouth, S.; Shishido, T.; Uehara, T.; Hayden, F. Exploring clinical and antiviral efficacy of baloxavir marboxil in a phase 3, randomized, double-blind, placebo- and active-controlled study of otherwise healthy adults/adolescents in seasonal influenza: impact on regional participants, treatment time and influenza type B virus infection (CAPSTONE-1 study). Open Forum Infect. Dis. 2018, 5, S48.

[17] Shionogi. Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications (CAPSTONE2). 2018, 07, 24. 2019, 02, 15. https//clinicaltrials.gov/ct2/show/NCT02949011term=Baloxavir+marboxil

[18] Ison, M.G. Phase 3 trial of baloxavir marboxil in high risk influenza patients (CAPSTONE-2 study). Open Forum Infect. Dis. 2018, 5, S764–S765.

[19] Japan Pharmaceuticals and Medical Devices Comprehensive Agency. Xofluza tablets. 2018, 02, 23. http://www. pmda.go.jp/PmdaSearch/iyaku Detail/Result Data Set PDF/340018_6250047F1022_1_01

[20] Drug Evaluation Department, Drug Safety and Environ-mental Health Bureau, Ministry of Health, Labour and Welfare, Japan. Ask Fruzac shackle review report. 2018, 02, 08. http://101.96.10.63/www.pmda.go.jp/drugs/2018/P20180312001/340018000_23000AMX00434000_ A100_1.pdf

流感新药巴洛沙韦的药理作用及临床评价

Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	常馨予, 韩丽娟, 刘洋, 范峥, 吴剑坤. 碳青霉烯类药物致血小板不良反应分析及相关文献回顾[J]. 中国药学(英文版), 2023, 32(10): 835-841.
[2]	赵峰, 王瑞, 张洪雄, 高太祥, 王楠. 越婢加术汤对阿霉素肾病大鼠肾脏保护作用的药效学研究[J]. 中国药学(英文版), 2022, 31(9): 711-717.
[3]	裴彦宇, 郝继晖, 段文琪, 郑宇静, 赵明, 杨莉萍. 利奈唑胺严重与致死性不良反应——案例报道的汇总分析[J]. 中国药学(英文版), 2022, 31(2): 153-161.
[4]	刘玥华, 薛章勤, 魏剑明, 魏若梦, 殷宝栋, 刘爱芹. 奥帕膦酸钠的药物合成及活性研究[J]. 中国药学(英文版), 2022, 31(11): 883-892.
[5]	李亚男, 郭雪, 袁叶, 董维冲, 杨秀岭. 头孢曲松游离浓度的测定及在预测肺组织浓度中的应用[J]. 中国药学(英文版), 2021, 30(7): 578-589.
[6]	袁叶, 于博, 张学琴, 李亚男, 王淑梅. 振源胶囊对辛伐他汀及其活性代谢物在大鼠体内的药动学影响[J]. 中国药学(英文版), 2020, 29(7): 494-503.
[7]	张金, 林玮玮, 吴委, 郭仙忠, 黄品芳, 林新华, 焦正, 王长连. 中国老年患者万古霉素群体药动学及个体化给药应用研究[J]. 中国药学(英文版), 2020, 29(4): 260-271.
[8]	常馨予, 郭涛, 郭桂明. CYP3A4基因多态性对健康受试者体内替硝唑药代动力学的影响[J]. 中国药学(英文版), 2020, 29(4): 272-279.
[9]	王圣鑫, 闫向丽, 郑昊圳, 余健烨, 余爱明, 沈晓, 王利胜. 微透析技术结合液质联用的不同剂量黄芪的补阳还五汤在脑缺血损伤大鼠脑药动学研究[J]. 中国药学(英文版), 2020, 29(2): 90-101.
[10]	邵淑容, 郭卫. 静脉注射人免疫球蛋白临床应用的不良反应之三年回顾性研究[J]. 中国药学(英文版), 2019, 28(1): 56-61.
[11]	蔡雁, 戴巍, 钦富华, 孙洁胤, 魏瑞龙. 染料木黄酮泊洛沙姆P407/P403混合胶束的制备及药动学研究[J]. 中国药学(英文版), 2018, 27(5): 342-351.
[12]	杨璐, 郭涛, 庄雪梅, 顾红燕. CYP2C9*2基因多态性对CYP3A4野生型健康回族受试者体内的氯沙坦及其活性代谢物E-3174的药动学影响[J]. 中国药学(英文版), 2018, 27(1): 14-21.
[13]	张杜娟, 陈克广, 张蕊, 袁桂艳, 王本杰, 郭瑞臣. 大鼠体内瑞舒伐他汀和瑞格列奈药动学和肝脏分布相互作用研究[J]. 中国药学(英文版), 2018, 27(1): 22-30.
[14]	曹思思, 邓阳, 蔡骅琳, 侯振彦, 颜苗, 张毕奎. HPLC-MS/MS法研究氨氯地平片在健康人体内的药动学和生物等效性[J]. 中国药学(英文版), 2017, 26(4): 291-297.
[15]	田溪, 袁叶, 苏子云, 李德强, 董维冲, 杨秀岭. 溶栓胶囊、血脂康胶囊、心元胶囊和松龄血脉康胶囊对大鼠体内氯吡格雷活性代谢产物药动学的影响[J]. 中国药学(英文版), 2017, 26(3): 187-195.